Results of one-year treat-to-target strategy in early psoriatic arthritis: Data of an open-label REMARCA study
Коротаева Т. В., Логинова Е. Y., Гетия Т. С., Насонов Е. Л.
Терапевтический архив
Т. 90, Вып. 5, С. 22-29
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.26442/terarkh201890522-29
Аннотация:
Objectives: To study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. Methods: 44 (M/F - 18/26) DMARD-na?ve patients (pts) with active EPsA, according to the CASPAR criteria, mean age 37.5±11.3 years, PsA duration 7 [4; 24] months, psoriasis duration 36 [12; 84] months, disease activity index (DAS) 3.78 [3.18; 4.67], DAS28 4.33 [3.67; 4.8] study were included. At the baseline and every other 3 months for total 12 months of therapy all pts underwent standard clinical examination, tender joint count (TJC), swollen joint count (SJC), patient pain VAS, patient/physiciańs global disease activity VAS, enthesitis by Leeds Enthesial Index (LEI)+Plantar Fascia (PF), dactylitis, Psoriasis Area Severity Index (PASI), body surface area (BSA), Health Assessment Questionnaire (HAQ), DAS, DAS28-C-RP, C-RP (mg/l). The dose of MTX s/c was escalated by 5 mg every 2 weeks from 10 mg/wk to appropriate dose 20-25 mg/wk according to the d
Ключевые слова:
Dactylitis; Early psoriatic arthritis; Enthesitis; Methotrexate; Minimal disease activity; Treatment-to-target strategy
adalimumab; antirheumatic agent; methotrexate; adult; human; middle aged; psoriatic arthritis; quality of life; severity of illness index; treatment outcome; Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Methotrexate; Middle Aged; Quality of Life; Severity of Illness Index; Treatment Outcome
Язык текста: Русский
ISSN: 2309-5342
Коротаева Т. В.
Логинова Е. Y. Е.Ю.
Гетия Т. С.
Насонов Е. Л. Евгений Львович 1948-
Korotaeva T. V.
Loginova E. Y. E.Yu.
Getiya T. S.
Nasonov E. L. Evgenij L`vovich 1948-
Results of one-year treat-to-target strategy in early psoriatic arthritis: Data of an open-label REMARCA study
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 90, Вып. 5 С. 22-29
2018
Статья
Dactylitis Early psoriatic arthritis Enthesitis Methotrexate Minimal disease activity Treatment-to-target strategy
adalimumab antirheumatic agent methotrexate adult human middle aged psoriatic arthritis quality of life severity of illness index treatment outcome Adalimumab Adult Antirheumatic Agents Arthritis, Psoriatic Humans Methotrexate Middle Aged Quality of Life Severity of Illness Index Treatment Outcome
Objectives: To study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. Methods: 44 (M/F - 18/26) DMARD-na?ve patients (pts) with active EPsA, according to the CASPAR criteria, mean age 37.5±11.3 years, PsA duration 7 [4; 24] months, psoriasis duration 36 [12; 84] months, disease activity index (DAS) 3.78 [3.18; 4.67], DAS28 4.33 [3.67; 4.8] study were included. At the baseline and every other 3 months for total 12 months of therapy all pts underwent standard clinical examination, tender joint count (TJC), swollen joint count (SJC), patient pain VAS, patient/physiciańs global disease activity VAS, enthesitis by Leeds Enthesial Index (LEI)+Plantar Fascia (PF), dactylitis, Psoriasis Area Severity Index (PASI), body surface area (BSA), Health Assessment Questionnaire (HAQ), DAS, DAS28-C-RP, C-RP (mg/l). The dose of MTX s/c was escalated by 5 mg every 2 weeks from 10 mg/wk to appropriate dose 20-25 mg/wk according to the d